IL4R
ENSG00000077238
Target class
Secreted protein
Chromosome
16
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Other names
- CD124
- Target name
- IL4R
- Gene name
- Interleukin 4 receptor
- Gene symbol
- IL4R
- Protein name
- Interleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha) (IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha) (sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Interleukin receptors
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 157.72
- Tissue specificity (Gini)
- 0.476
- Tissue specificity (tau)
- 0.753
- KEGG gene identifiers
- hsa:3566
- Protein interaction confidence
- 0.824169
- Protein interaction partners
- 65
- R-HSA-6785807
- R-HSA-9976102
- End position
- 27364811
- Start position
- 27313462
- Chromosome
- 16
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein.
- SUBCELLULAR LOCATION: [Isoform 2]: Secreted.
- Plasma membrane
- Tissue specificity (tau)
- 0.75293
- Expression inequality (Gini)
- 0.47646
Expression in transcripts per million
- Lung
- 157.72
- Whole Blood
- 149.32
- Colon - Sigmoid
- 114.84
- Spleen
- 109.49
- Esophagus - Muscularis
- 97.33
Expression in transcripts per million
- Lung157.72
- Whole Blood149.32
- Colon - Sigmoid114.84
- Spleen109.49
- Esophagus - Muscularis97.33
- Esophagus - Gastroesophageal Junction96.99
- Bladder90.37
- Esophagus - Mucosa70.79
- Colon - Transverse69.24
- Uterus68.76
- Vagina64.92
- Fallopian Tube64.85
- Cervix - Ectocervix60.33
- Artery - Coronary57.93
- Prostate57.85
- Small Intestine - Terminal Ileum57.75
- Cervix - Endocervix55.14
- Adipose - Visceral (Omentum)54.38
- Liver52.95
- Artery - Tibial52.75
- Adipose - Subcutaneous48.97
- Artery - Aorta44.62
- Breast - Mammary Tissue44.26
- Adrenal Gland35.68
- Thyroid34.28
And 29 more, listed on the interactive page.
- GO:0006955
- GO:0007165
- GO:0007259
- GO:0035771
- GO:0035772
- GO:0042531
- GO:0005886
- GO:0043235
- GO:0004913
- GO:0005515
Related records
Trials (261)
- A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers
- A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps
- A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
- A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
- A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
- A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
- A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
- A Phase I Study of 9MW4113 Injection Versus Dupixent®
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
- A Phase III Study of GS101 Injection to Dupixent®
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
- A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps
- A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
- A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
- A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Drugs (2)
- Cintredekin besudotox Interleukin 13 receptor binding agent
- Dupilumab Interleukin-4 receptor subunit alpha antagonist